摘要
目的:研究强直性脊柱炎(AS)患者行阿司匹林+正清风痛宁治疗的效果。方法:选取鹿邑真源医院2019年5月-2021年12月收治的80例AS患者,按照随机取样法分为单一组(阿司匹林,n=40)、研讨组(阿司匹林+正清风痛宁,n=40),比较两组中医症候积分、临床指标、疾病恢复情况及临床疗效。结果:两组用药后肢冷畏寒、腰膝酸软、腰骶关节疼痛、活动受限积分低于用药前,且研讨组低于单一组(P<0.05);两组用药后BASFI、VAS评分、ESR及CRP低于用药前,且研讨组低于单一组(P<0.05);两组用药后枕墙距、晨僵时间,胸廓活动度优于用药前,且研讨组优于单一组(P<0.05);研讨组总有效率高于单一组(P<0.05)。结论:阿司匹林+正清风痛宁治疗AS患者的疗效确切,可降低中医证候积分、改善脊柱功能,降低急性时相反应物水平、缩短晨僵时间,值得临床应用。
Objective:To study the effect of aspirin+Zhengqing Fengtongning in patients with ankylosing spondylitis(AS).Methods:A total of 80 AS patients admitted to Luyi Zhenyuan Hospital from May 2019 to December 2021 were selected and divided into a single group(aspirin,n=40)and a discussion group(aspirin+Zhengqing Fengtongning,n=40)according to the random sampling method.The TCM symptom scores,clinical indicators,disease recovery and clinical efficacy of the two groups were compared.Results:The scores of cold aversion of hind limbs,soreness and weakness of waist and knees,lumbosacral joint pain and activity limitation in the two groups were lower than those before treatment,and those in the study group were lower than those in the single group(P<0.05).The BASFI,VAS score,ESR and CRP of the two groups after treatment were lower than those before treatment,and the study group was lower than the single group(P<0.05).After treatment,the occiput-wall distance,morning stiffness time and thoracic mobility of the two groups were better than those before treatment,and the study group was better than the single group(P<0.05).The total effective rate of the study group was higher than that of the single group(P<0.05).Conclusion:Aspirin+Zhengqing Fengtongning is effective in treating AS patients,which can reduce TCM syndrome scores,improve spinal function,reduce acute phase reactant levels,shorten morning stiffness time,and is worthy of clinical application.
作者
李涛
张海勇
史守禄
蔡松涛
LI Tao;ZHANG Haiyong;SHI Shoulu;CAI Songtao(Department of Spine and Joint Surgery,Luyi Zhenyuan Hospital,Zhoukou 477200,Henan,China;Department of Arthrology,Zhengzhou Orthopedic Hospital,Zhengzhou 450000,Henan,China)
出处
《中国药物滥用防治杂志》
CAS
2024年第1期155-159,共5页
Chinese Journal of Drug Abuse Prevention and Treatment